The study is designed to evaluate the safety and clinical activity of NXP900 in combination with osimertinib in patients with ...
Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for the restoration of peripheral nerve function, today announced that the company will be ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback